GlassScriptPhysician profile
Stephen H Paul
NPI 1821060286
$17,637.30
in general payments reported to CMS, 2019-2025
41 companies · $3,322 in 2025
The $3,322 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $908 · 2021: $2,077 · 2022: $3,576 · 2023: $2,938 · 2024: $3,148 · 2025: $3,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,341 · Education: $66.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,341.32 |
| Education | $66.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,731.91 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,487.64 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,866.09 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,843.70 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $1,084.74 | 2021-2023 | |
| Celgene Corporation | $530.52 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $509.84 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $507.43 | 2022-2025 | |
| Pfizer INC. | $487.63 | 2019-2025 | |
| Madrigal Pharmaceuticals | $468.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $320.89 | 2020-2025 | Sutab, Suflave |
| Qol Medical, LLC | $319.79 | 2022-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $315.27 | 2021-2022 | |
| Vivus LLC | $314.94 | 2019-2025 | Pancreaze |
| Gilead Sciences, INC. | $302.19 | 2019-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $252.69 | 2019-2024 | Dificid, Recarbrio, Zerbaxa |
| Phathom Pharmaceuticals, INC. | $248.05 | 2024-2025 | Voquezna |
| Allergan, INC. | $196.86 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $179.54 | 2021-2024 | Linzess |
| Lilly USA, LLC | $170.06 | 2024-2025 | Omvoh |
| Neuraxis, INC. | $167.40 | 2025 | |
| Aimmune Therapeutics, INC. | $159.76 | 2024-2025 | Zenpep |
| Amgen INC. | $127.33 | 2022-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $113.19 | 2024-2025 | Iqirvo, Bylvay |
| Redhill Biopharma INC. | $108.87 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $99.93 | 2019-2024 | |
| Medtronic, INC. | $83.31 | 2022-2025 | Bravo |
| Janssen Pharmaceuticals, INC | $78.86 | 2022 | |
| Organon LLC | $78.39 | 2021-2025 | Hadlima |
| Ucb, INC. | $76.22 | 2019 | |
| Shionogi INC | $64.72 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $58.04 | 2023-2025 | Rebyota |
| Alfasigma USA, INC. | $57.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.42 | 2023-2024 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $49.15 | 2021-2023 | Givlaari |
| Evoke Pharma, INC. | $35.51 | 2023-2024 | Gimoti |
| Sirtex Medical INC | $26.54 | 2024 | Sir-Spheres Microspheres |
| Azurity Pharmaceuticals, INC. | $16.06 | 2025 | Suflave |
| Echosens North America, INC. | $16.02 | 2022 | |
| Cook Medical LLC | $13.28 | 2020 | |
| Shire North American Group INC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.